Cell counting in cell therapy research and generation is a challenge. Unlike traditional bioprocesses that rely on the expansion of cell lines in a bioreactor, autologous cell therapies are made from individual donor tissues that undergo multi-step manufacturing processes. Therefore, during the manufacture of these therapies a significant diversity of samples is observed.

Under similar conditions, traditional cell counting based on brightfield microscopy and trypan blue exclusion fails to provide consistent measurements of cell count and viability.

The NucleoCounter® counts cells by identifying nuclei stained with fluorescent DNA-binding dyes, resulting in a strong, cell-specific signal. In this way, NucleoCounter® can quantify their number and viability under difficult conditions often encountered in cell therapy processing, such as the presence of red blood cells, sorting beads or clusters of cells. With its GMP-ready software, NucleoCounter® is ideal for the development of cell therapies.